Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV
Authors:
- Ronald J. EllisRERonald J. Ellis
- Monica DiazMDMonica Diaz
- for the CNS Antiretroviral Therapy Effects Research (CHARTER) Study GroupFGfor the CNS Antiretroviral Therapy Effects Research (CHARTER) Study Group
Open Access
- 3 July 2020
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (7) , 1166-1173
Abstract
Objective: Distal sensory polyneuropathy (DSP) and neuropathic pain are important clinical concerns in virally suppressed people with HIV. We determined how these conditions evolved, what factors influenced their evolution, and their clinical impact.Methods: Ambulatory, community‐dwelling HIV seropositive individuals were recruited at six research centers. Clinical evaluations at baseline and 12 years later determined neuropathy signs and distal neuropathic pain (DNP). Additional assessments measured activities of daily living and quality of life (QOL). Factors potentially associated with DSP and DNP progression included disease severity, treatment, demographics, and co‐morbidities. Adjusted odds ratios were calculated for follow‐up neuropathy outcomes.Results: Of 254 participants, 21.3% were women, 57.5% were non‐white. Mean baseline age was 43.5 years. Polyneuropathy prevalence increased from 25.7% to 43.7%. Of 173 participants initially pain‐free, 42 (24.3%) had incident neuropathic pain. Baseline risk factors for incident pain included unemployment (OR [95% CI], 5.86 [1.97, 17.4]) and higher baseline body mass index (BMI) (1.78 [1.03, 3.19] per 10‐units). Participants with neuropathic pain at follow‐up had significantly worse QOL and greater dependence in activities of daily living than those who remained pain‐free.Interpretation: HIV DSP and neuropathic pain increased in prevalence and severity over 12 years despite high rates of viral suppression. The high burden of neuropathy included disability and poor life quality. However, substantial numbers remained pain‐free despite clear evidence of neuropathy on exam. Protective factors included being employed and having a lower BMI. Implications for clinical practice include promotion of lifestyle changes affecting reversible risk factors.Keywords
Funding Information
- National Institutes of Health (HHSN271201000030C, HHSN271201000036C, N01 MH22005, R01 MH107345)
This publication has 34 references indexed in Scilit:
- The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US womenJournal of the Neurological Sciences, 2012
- Peripheral Vascular Disease and Peripheral Neuropathy in Individuals With Cardiometabolic Clustering and ObesityDiabetes Care, 2011
- Peripheral neuropathy in HIV: prevalence and risk factorsAIDS, 2011
- HIV Neuropathy Risk Factors and Symptom Characterization in Stavudine-Exposed South AfricansJournal of Pain and Symptom Management, 2011
- Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathyPain, 2010
- HIV neuropathy in South Africans: Frequency, characteristics, and risk factorsMuscle & Nerve, 2010
- Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapyNeurology, 2009
- Standardizing Assessment of Elderly People in Acute Care: The interRAI Acute Care InstrumentJournal of the American Geriatrics Society, 2008
- Prevalence of and risk factors for HIV‐associated neuropathy in Melbourne, Australia 1993–2006HIV Medicine, 2007
- The impact of HIV-associated neuropsychological impairment on everyday functioningJournal of the International Neuropsychological Society, 2004